ES2599395T3 - Formulación estable de pexiganano - Google Patents

Formulación estable de pexiganano Download PDF

Info

Publication number
ES2599395T3
ES2599395T3 ES13803656.1T ES13803656T ES2599395T3 ES 2599395 T3 ES2599395 T3 ES 2599395T3 ES 13803656 T ES13803656 T ES 13803656T ES 2599395 T3 ES2599395 T3 ES 2599395T3
Authority
ES
Spain
Prior art keywords
formulation
surfactant
tween
alcohol
hydrophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13803656.1T
Other languages
English (en)
Spanish (es)
Inventor
Nayan Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PLX Pharma Winddown Corp
Original Assignee
Dipexium Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dipexium Pharmaceuticals LLC filed Critical Dipexium Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2599395T3 publication Critical patent/ES2599395T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46N-acyl derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES13803656.1T 2012-06-12 2013-06-10 Formulación estable de pexiganano Active ES2599395T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/494,295 US8530409B1 (en) 2012-06-12 2012-06-12 Stable pexiganan formulation
US201213494295 2012-06-12
PCT/US2013/044957 WO2013188286A1 (en) 2012-06-12 2013-06-10 Stable pexiganan formulation

Publications (1)

Publication Number Publication Date
ES2599395T3 true ES2599395T3 (es) 2017-02-01

Family

ID=49084089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13803656.1T Active ES2599395T3 (es) 2012-06-12 2013-06-10 Formulación estable de pexiganano

Country Status (26)

Country Link
US (2) US8530409B1 (https=)
EP (1) EP2858721B1 (https=)
JP (1) JP5876191B2 (https=)
KR (1) KR101622524B1 (https=)
CN (1) CN104602762B (https=)
AU (1) AU2013274561B2 (https=)
BR (1) BR112014030993A2 (https=)
CA (1) CA2876668C (https=)
CY (1) CY1118277T1 (https=)
DK (1) DK2858721T3 (https=)
EA (1) EA028002B1 (https=)
ES (1) ES2599395T3 (https=)
HR (1) HRP20161440T1 (https=)
HU (1) HUE030665T2 (https=)
IL (1) IL236151A (https=)
LT (1) LT2858721T (https=)
MX (1) MX345263B (https=)
NZ (1) NZ703176A (https=)
PL (1) PL2858721T3 (https=)
PT (1) PT2858721T (https=)
RS (1) RS55286B1 (https=)
SG (1) SG11201408055PA (https=)
SI (1) SI2858721T1 (https=)
SM (1) SMT201600411B (https=)
WO (1) WO2013188286A1 (https=)
ZA (1) ZA201500117B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530409B1 (en) * 2012-06-12 2013-09-10 Dipexium Pharmaceuticals LLC Stable pexiganan formulation
GB201505393D0 (en) * 2015-03-30 2015-05-13 Secr Defence Antimicrobal peptide formulations
CN111925430B (zh) * 2020-08-18 2022-05-24 中国海洋大学 抗菌肽及其应用
US20230106943A1 (en) * 2021-09-17 2023-04-06 Peptilogics, Inc. Engineered antimicrobial peptides and usage thereof
KR102773934B1 (ko) * 2021-11-25 2025-02-26 광주여자대학교 산학협력단 Msi-78 펩타이드를 유효성분으로 포함하는 항균용 화장료 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4169703A (en) * 1978-08-03 1979-10-02 Syntex (U.S.A.) Inc. Oxidative red hair dye
US5912231A (en) * 1989-07-07 1999-06-15 Scripps Clinic And Research Foundation Substitution analogues of magainin peptides
TW460296B (en) * 1994-09-01 2001-10-21 Janssen Pharmaceutica Nv Topical ketoconazole emulsion compositions without sodium sulfite
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
AU2005221427B2 (en) * 2004-03-18 2008-09-25 Panacea Biotec Ltd. Novel compositions for topical delivery
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
WO2009070564A2 (en) * 2007-11-27 2009-06-04 Macrochem Corporation Compositions and methods for prevention of infection in transcutaneous osseointegrated implants
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2012174373A1 (en) * 2011-06-16 2012-12-20 Dipexium Pharmaceuticals Methods of treating and inhibiting pathogens with resistance-mechanisms
US8530409B1 (en) * 2012-06-12 2013-09-10 Dipexium Pharmaceuticals LLC Stable pexiganan formulation

Also Published As

Publication number Publication date
KR20150043286A (ko) 2015-04-22
EP2858721A4 (en) 2015-12-09
AU2013274561B2 (en) 2015-09-10
HRP20161440T1 (hr) 2016-12-16
LT2858721T (lt) 2016-12-12
SMT201600411B (it) 2017-01-10
EP2858721A1 (en) 2015-04-15
NZ703176A (en) 2015-08-28
EA028002B1 (ru) 2017-09-29
RS55286B1 (sr) 2017-03-31
BR112014030993A2 (pt) 2017-06-27
AU2013274561A1 (en) 2015-01-22
CA2876668C (en) 2017-12-05
PL2858721T3 (pl) 2017-02-28
US20140038882A1 (en) 2014-02-06
IL236151A0 (en) 2015-01-29
CA2876668A1 (en) 2013-12-19
EA201492280A1 (ru) 2015-05-29
US8530409B1 (en) 2013-09-10
DK2858721T3 (en) 2016-11-28
MX345263B (es) 2017-01-23
ZA201500117B (en) 2016-10-26
SG11201408055PA (en) 2015-01-29
JP5876191B2 (ja) 2016-03-02
CN104602762A (zh) 2015-05-06
IL236151A (en) 2016-06-30
WO2013188286A1 (en) 2013-12-19
PT2858721T (pt) 2016-11-17
HUE030665T2 (en) 2017-05-29
SI2858721T1 (sl) 2017-01-31
HK1210078A1 (en) 2016-04-15
MX2014015199A (es) 2015-08-14
EP2858721B1 (en) 2016-08-17
CN104602762B (zh) 2017-04-05
CY1118277T1 (el) 2017-06-28
JP2015521599A (ja) 2015-07-30
KR101622524B1 (ko) 2016-05-18

Similar Documents

Publication Publication Date Title
ES2599395T3 (es) Formulación estable de pexiganano
KR101803902B1 (ko) 세라마이드를 포함하는 피부 외용제 조성물
US20220287946A1 (en) Anhydrous skin care composition comprising retinol and/or bakuchiol
BR112013025120B1 (pt) Composição e processo de tratamento cosmético não-terapêutico
JP2017226664A (ja) Dgla、15−ohepaおよび/または15−hetreを含む医薬組成物、ならびにその使用方法
ES2863307T3 (es) Composición tópica que comprende extractos vegetales
IL316851A (en) Preparations that are pharmaceutical emulsions for topical use containing 5,3-dihydroxy-4-isopropyl-trans-stilbene and their use for the treatment or prevention of dermatological conditions or disorders
ES2803924T3 (es) Composición para aplicación tópica con actividad antifúngica
BR112013025121B1 (pt) Composição e processo de tratamento cosmético
EP2817005A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
JP2024517463A (ja) ニコチンアミドアデニンジヌクレオチド(nad)組成物、それらの製造方法、及びそれらの使用方法
KR20140091690A (ko) Dgla 및/또는 15-hetre을 포함하는 약제학적 조성물 및 그의 사용 방법
KR20170032475A (ko) 화장품 조성물 및 멜라닌 합성을 억제하기 위한 방법
Ramanauskiene et al. Analysis of the antimicrobial activity of propolis and lysozyme in semisolid emulsion systems
AU2006287746A1 (en) Novel skin care compositions
KR20130055182A (ko) 여드름 개선용 조성물 및 이를 포함하는 여드름 개선용 키트
US20240342066A1 (en) High potency emulsions
US8394428B1 (en) Formulations and methods for preventing eyebrow hair loss
KR20110138709A (ko) 5-아미노레불린산 또는 이의 에스테르를 포함하는 여드름 개선용 조성물
BR112018011580B1 (pt) Compostos de éster, compostos de amida, composição e uso de pelo menos um composto
CN105307626A (zh) 预防或减少皮肤色素沉着并且淡化肤色的组合物及其用途
JP2017171642A (ja) 外用組成物
KR20210124659A (ko) 페놀계 화합물을 함유하는 보존제 및 이를 포함하는 조성물
ES2964637T3 (es) Preparación antimicrobiana que comprende bispiridinioalcanos, éteres de 1- o 2-(alquil C1 a C24)-glicerol y alcano-1,2-dioles
US10231921B2 (en) Use of an essential oil of Origanum majorana, as an agent for treating and/or preventing greasy skin and/or the associated aesthetic skin defects